Mounjaro

Mounjaro 5mg/0.5ml is a prescription tirzepatide injection developed by Eli Lilly. It belongs to the GIP and GLP-1 receptor agonist category and is designed for professional medical use as part of metabolic health and diabetes management protocols.

Each 0.5ml dose contains 5mg of tirzepatide. Mounjaro is administered by subcutaneous injection and is commonly used under medical supervision together with diet and exercise to support blood sugar control in appropriate patients. Regulatory product information also lists Mounjaro 5mg as a solution for injection containing 5mg tirzepatide in 0.5ml.

Unlike Botulinum Toxin, which relaxes targeted muscles, or dermal fillers, which restore volume and enhance facial contours, Mounjaro belongs to the prescription metabolic treatment category. It should not be positioned as a cosmetic injectable, filler, skin booster, or fat-dissolving aesthetic product.

Key Benefits

• Prescription tirzepatide injection by Eli Lilly
• GIP and GLP-1 receptor agonist
• Supports metabolic health and blood sugar management under medical supervision
• Once-weekly injectable treatment format according to prescribing information
• Not a Botox product
• Not a dermal filler
• Not a skin booster or fat-dissolving injection

Prescription Use Only

This product is a prescription medicine and should only be used under the supervision of a qualified healthcare professional. Product authenticity, cold-chain storage, batch number, expiry date, registration documents, and local legal requirements should be carefully verified before distribution or use.